Table 1.

Non-recommended and low value drugs included in the study

Cancer drugs*	Basis for inclusion
Non-recommended
Denosumab for castration sensitive prostate cancer	CALGB 90202,25 STAMPEDE,26 NCCN guidelines,28 expert opinion31 32
Granulocyte colony stimulating factors with chemotherapy that is low risk for neutropenic fever	NCCN guidelines,33 ASCO Choosing Wisely,34 ASCO guidelines35
Low value
Nab-paclitaxel for breast or lung cancer	NCT00540514,36 CALGB 4050237 38
Branded drug when generic or biosimilar version is available†	NA

ASCO=American Society of Clinical Oncology; CALGB=Cancer and Leukemia Group B trial; NA=not applicable; NCCN=National Comprehensive Cancer Network; NCT=national clinical trial; STAMPEDE=Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy.

^*Clinical trial evidence, clinical practice guidelines, and expert opinion applied in identifying the service as non-recommended or love value is presented.

^†Based on assumption that generic and biosimilar drugs are therapeutically equivalent and have lower prices than branded drugs.